PolyActiva has completed a phase 1 clinical study evaluating the Latanoprost FA SR ocular implant for glaucoma treatment, according to a press release.
The implant was well tolerated in the eight study subjects and persisted for the 6-month treatment period. No significant safety findings were observed.
After the treatment period, the implant biodegrades over 6 weeks, which may allow for repeat dosing. The aim of the implant is to “provide a constant daily therapeutic dose of latanoprost free acid” for 6 months, the release said.
“Our goal is to improve the reduction of
Uncategorized